Stimulation of the Pro-Resolving Receptor Fpr2 Reverses Inflammatory Microglial Activity by Suppressing NFκB...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Microglia-driven neuroinflammation contributes to neuronal death in neurodegenerative diseases.
• Exploiting inflammatory resolution pathways, like formyl peptide receptor 2 (Fpr2), offers a potential therapeutic strategy.
• The therapeutic role of Fpr2 in neurodegeneration is currently unclear.

Purpose of the Study:

• To investigate the therapeutic potential of targeting Fpr2 to reverse microglial activation.
• To determine if Fpr2 activation can mitigate lipopolysaccharide (LPS)-induced neuroinflammation.

Main Methods:

• Murine primary and immortalised BV2 microglia were exposed to LPS.
• Subsequent treatment with the Fpr2 agonist C43 was administered.
• Mechanistic studies involved assessing p38 MAPK phosphorylation and NFκB nuclear translocation via IκBα degradation.

Main Results:

• LPS exposure induced pro-inflammatory changes and reactive oxygen species (ROS) production in microglia.
• C43 treatment significantly attenuated LPS-induced pro-inflammatory responses.
• C43 acted via p38 MAPK phosphorylation, reducing NFκB nuclear translocation by preventing IκBα degradation.

Conclusions:

• Fpr2 is a potential target for controlling microglial pro-inflammatory activity.
• Targeting Fpr2 demonstrates proof-of-concept for treating neuroinflammatory diseases.
• Fpr2 agonists may offer a novel therapeutic approach for neuroinflammation.